PersonFounderExecutive
Stig Hansen
Stig K. Hansen is a Danish-American biochemist and serial biotech founder who co-founded Kimia Therapeutics in 2023, a Berkeley-based precision chemistry company applying machine learning and automated synthesis to drug discovery. He previously co-founded and led Carmot Therapeutics for 15 years, inventing Chemotype Evolution technology that contributed to LUMAKRAS - the world's first FDA-approved KRAS G12C inhibitor for non-small cell lung cancer. Carmot was acquired by Roche for up to $3.1 billion in January 2024. At Kimia, Hansen is pioneering the ATLAS platform (AcTive Learning with Automated Synthesis and Screening), which integrates high-throughput chemistry, genome editing, and AI to map druggable chemical space at unprecedented scale. The company raised a $55 million Series A in December 2023 led by The Column Group and Dimension.
biotechdrug-discoveryceofounderkimia-therapeuticscarmot-therapeutics
